MUC16 C terminal fragment activates YAP1 through Src signaling to promote gallbladder cancer growth

• Published in: MedComm - Oncology 2023-12, Vol.2 (4), p.n/a
• Main Authors: Fan, Kun, Wang, Jiwen, Zhu, Kaihua, Ni, Xiaojian, Shen, Sheng, Gong, Zijun, Bo, Xiaobo, Wang, Changcheng, Cheng, Xi, Zhang, Cheng, Suo, Tao, Liu, Han, Ni, Xiaoling, Liu, Houbao
• Format: Article
• Language: English
• Subjects: Amino acids; Breast cancer; Cancer therapies; Cytoplasm; Gallbladder cancer; Hippo pathway; Kinases; Localization; Medical prognosis; Metastasis; MUC16c; Pancreatic cancer; Phosphorylation; Plasmids; Polypeptides; Proteins; Src; Tumors; YAP1
• ISSN: 2769-6448; 2769-6448
• DOI: 10.1002/mog2.54

The Hippo pathway is crucial to organ size control and its dysregulation contributes to tumorigenesis. The aberrant activation of YAP1 was identified in gallbladder cancer (GBC). However, the underlying mechanism and role in GBC remains unclear. The C terminal fragment of Mucin16, also known as carbohydrate antigen 125 (CA125) encoded product, MUC16c, plays extensive roles in tumor initiation and development. Our study showed that MUC16c binding with 14‐3‐3ε disrupted the interaction of 14‐3‐3ε and phosphorylated yes‐associated protein 1 (YAP1), which led to the activation of YAP1 in GBC. Furthermore, MUC16c decreased the phosphorylation of YAP1 at serine 397 (ser397) by inhibiting LATS1, which upregulated YAP1 protein stability. Interestingly, there was a potential Src kinase site in the MUC16c fragment. The MUC16c_del15Y polypeptides with the deletion of the Src kinase site promoted the interaction of YAP1 with 14‐3‐3ε and downregulated the YAP1 protein levels. Consistently, SU6656, a Src kinase inhibitor also blocked the activation of YAP1 by MUC16c. The MUC16c_del15Y polypeptides decreased GBC cell proliferation in vitro and the growth of xenograft tumors in vivo. Our study revealed the underlying mechanism of the activation of MUC16c on YAP1 mediated by Src signaling and the antitumor effect of MUC16c_del15Y, providing a potential target for GBC therapy. In this paper, we reported that an underlying mechanism of the C terminal polypeptide of MUC16 encoded product (MUC16c) activated YAP1 to promote gallbladder cancer (GBC), which was regulated by Src signaling. We also identified the antitumor effect of MUC16c_del15Y polypeptides by inhibiting YAP1 in GBC.